Medicine and Dentistry
Neoplasm
100%
Positron Emission Tomography
74%
Gamma Urogastrone
48%
Breast Cancer
42%
Zirconium 89
37%
Metastatic Breast Cancer
34%
Molecular Imaging
33%
Positron Emission Tomography
32%
Epidermal Growth Factor Receptor 2
29%
Mesothelin
28%
Pancreas Cancer
28%
Ovarian Cancer
28%
Radioactive Tracer
25%
Biological Marker
25%
Malignant Neoplasm
21%
Metastatic Carcinoma
20%
Diagnosis
20%
Fluorodeoxyglucose F 18
18%
Bone Metastasis
17%
Immunoglobulin
16%
Antibody-Drug Conjugate
16%
Trastuzumab
15%
Standardized Uptake Value
15%
Bone Scintigraphy
15%
Lung Nodule
14%
Bone Lesion
14%
Estrogen Receptor
14%
Programmed Death-Ligand 1
14%
Clinical Decision Making
14%
Reproducibility
14%
Bronchoscopy
14%
Transforming Growth Factor Beta Antibody
14%
Fresolimumab
14%
Progesterone Receptor
14%
Ganglioglioma
14%
Treatment Response
14%
Atezolizumab
14%
Edetic Acid
14%
Solid Malignant Neoplasm
14%
Technetium-99
14%
Decalcification
14%
Epidermal Growth Factor Receptor 3
14%
Lumretuzumab
14%
Cancer Immunotherapy
14%
Immunohistochemistry
14%
Immunotherapy
9%
Epidermal Growth Factor Receptor
9%
Monoclonal Antibody
7%
Tumor Microenvironment
7%
Growth Factor
7%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
62%
Zirconium 89
33%
Breast Cancer
28%
Gamma Urogastrone
26%
Malignant Neoplasm
26%
Monoclonal Antibody
21%
Biological Marker
19%
Tracer
18%
Trastuzumab
17%
Epidermal Growth Factor Receptor 2
14%
Pandemic
14%
Immunotherapy
14%
Immune Checkpoint Inhibitor
14%
Biodistribution
14%
Glioma
14%
Programmed Death 1 Ligand 1
14%
Non Small Cell Lung Cancer
14%
Immunoglobulin
14%
Transforming Growth Factor Beta Antibody
14%
Fresolimumab
14%
Drug Development
10%
Epidermal Growth Factor Receptor
9%
Clinical Trial
8%
Cancer Staging
7%
Growth Factor Receptor
7%
Clinical Research
7%
Antibodies
7%
Hormone Receptor
7%
Multiple Cancer
7%
Epidermal Growth Factor Receptor 3
7%
Tumor Microenvironment
6%
Growth Factor
6%
Keyphrases
Positron Emission Tomography
33%
HER3
31%
Molecular Imaging
28%
Zr-89
28%
Whole-body
21%
Navigational Bronchoscopy
14%
Transforming Growth Factor-β
14%
Uptake Quantification
14%
Solid Tumors
14%
Atezolizumab
14%
High-grade Glioma
14%
Fresolimumab
14%
Cancer Immunotherapy
14%
On the Move
14%
Breast Cancer Bone Metastasis
14%
Antibody Uptake
14%
Human Epidermal Growth Factor Receptor 2 (HER2)
14%
Human Epidermal Growth Factor Receptor 2-negative
14%
Metastatic Breast Cancer
14%
Tumor
9%
Solitary Pulmonary Nodule
8%
Pharmacodynamics
7%
After Injection
7%
SUVmax
6%
Immunohistochemistry
6%
Standardized Uptake Value
5%
Whole-body Distribution
5%
HER Family
5%
Metastasis
5%
